Tags

Type your tag names separated by a space and hit enter

Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
Pediatr Infect Dis J. 2007 Nov; 26(11):1001-5.PI

Abstract

OBJECTIVE

To evaluate the safety and immunogenicity of revaccination with locally-produced Vi polysaccharide vaccine 3 years after the first dose in Chinese children aged 9 to 14 years.

METHODS

A randomized, placebo-controlled trial was conducted in Suzhou, Jiangsu, China. Six hundred and sixty-seven eligible children who had previously received a primary dose of Vi vaccine were randomly assigned to receive 1 dose of 30 mug Vi vaccine or placebo. In addition, 331 eligible children received 1 dose of Vi polysaccharide vaccine as a primary vaccination. Adverse events were followed for 28 days after vaccination. Serum samples were collected from a subgroup of participants on day 0 and day 28, and Vi antibodies were analyzed using a passive hemagglutination method.

RESULTS

Revaccination was found to be safe and immunogenic. No severe adverse events were observed. A significant increase in antibody titers after vaccination was observed among children who had and had not been previously vaccinated. Twenty-eight days after injection, the seropositive rate was 79% in both revaccination and primary injection groups; the geometric mean antibody titer was 1:40 in the primary injection group and 1:29 in the revaccination group (P = 0.24). Although the difference of attained geometric mean titers in follow-up sera was not significantly different in these 2 groups, the fold-rise of these titers from baseline was significantly higher in the primary injection group than in the revaccination group (7.7 versus 3.1, P < 0.001).

CONCLUSION

We found that revaccination using the locally produced Vi polysaccharide vaccine among Chinese school-aged children was safe and increased antibody titers. Revaccination can be used to extend the duration of protection provided by Vi polysaccharide vaccine.

Authors+Show Affiliations

Jiangsu Provincial Center for Disease Prevention and Control, Nanjing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17984806

Citation

Zhou, Wei-Zhong, et al. "Revaccination With Locally-produced Vi Typhoid Polysaccharide Vaccine Among Chinese School-aged Children: Safety and Immunogenicity Findings." The Pediatric Infectious Disease Journal, vol. 26, no. 11, 2007, pp. 1001-5.
Zhou WZ, Koo HW, Wang XY, et al. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings. Pediatr Infect Dis J. 2007;26(11):1001-5.
Zhou, W. Z., Koo, H. W., Wang, X. Y., Zhang, J., Park, J. K., Zhu, F., Deen, J., Acosta, C. J., Chen, Y., Wang, H., Galindo, C. M., Ochiai, L., Park, T., von Seidlein, L., Xu, Z. Y., & Clemens, J. D. (2007). Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings. The Pediatric Infectious Disease Journal, 26(11), 1001-5.
Zhou WZ, et al. Revaccination With Locally-produced Vi Typhoid Polysaccharide Vaccine Among Chinese School-aged Children: Safety and Immunogenicity Findings. Pediatr Infect Dis J. 2007;26(11):1001-5. PubMed PMID: 17984806.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings. AU - Zhou,Wei-Zhong, AU - Koo,Hye-Won, AU - Wang,Xuan-Yi, AU - Zhang,Jun, AU - Park,Jin-Kyung, AU - Zhu,Fengcai, AU - Deen,Jacqueline, AU - Acosta,Camilo J, AU - Chen,Yan, AU - Wang,Hua, AU - Galindo,Claudia M, AU - Ochiai,Leon, AU - Park,Taesung, AU - von Seidlein,Lorenz, AU - Xu,Zhi-Yi, AU - Clemens,John D, PY - 2007/11/7/pubmed PY - 2007/12/21/medline PY - 2007/11/7/entrez SP - 1001 EP - 5 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 26 IS - 11 N2 - OBJECTIVE: To evaluate the safety and immunogenicity of revaccination with locally-produced Vi polysaccharide vaccine 3 years after the first dose in Chinese children aged 9 to 14 years. METHODS: A randomized, placebo-controlled trial was conducted in Suzhou, Jiangsu, China. Six hundred and sixty-seven eligible children who had previously received a primary dose of Vi vaccine were randomly assigned to receive 1 dose of 30 mug Vi vaccine or placebo. In addition, 331 eligible children received 1 dose of Vi polysaccharide vaccine as a primary vaccination. Adverse events were followed for 28 days after vaccination. Serum samples were collected from a subgroup of participants on day 0 and day 28, and Vi antibodies were analyzed using a passive hemagglutination method. RESULTS: Revaccination was found to be safe and immunogenic. No severe adverse events were observed. A significant increase in antibody titers after vaccination was observed among children who had and had not been previously vaccinated. Twenty-eight days after injection, the seropositive rate was 79% in both revaccination and primary injection groups; the geometric mean antibody titer was 1:40 in the primary injection group and 1:29 in the revaccination group (P = 0.24). Although the difference of attained geometric mean titers in follow-up sera was not significantly different in these 2 groups, the fold-rise of these titers from baseline was significantly higher in the primary injection group than in the revaccination group (7.7 versus 3.1, P < 0.001). CONCLUSION: We found that revaccination using the locally produced Vi polysaccharide vaccine among Chinese school-aged children was safe and increased antibody titers. Revaccination can be used to extend the duration of protection provided by Vi polysaccharide vaccine. SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/17984806/Revaccination_with_locally_produced_vi_typhoid_polysaccharide_vaccine_among_chinese_school_aged_children:_safety_and_immunogenicity_findings_ DB - PRIME DP - Unbound Medicine ER -